1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Alzheimer's Drug Discovery Foundation (Goodes Prize) is a funding program from the Alzheimer's Drug Discovery Foundation (ADDF) that supports academic centers and biotechnology companies worldwide advancing therapeutic and biomarker development for Alzheimer's disease and related dementias.
Using a venture philanthropy model, ADDF makes investments rather than traditional grants, typically seeking a share of commercial returns from academic-funded research or purchasing convertible notes or equity in biotech companies.
Active focus areas include IND-enabling studies and early-stage clinical trials for novel and repurposed drugs, plasma, CSF, neuroimaging, and digital biomarker development, and clinical trials evaluating whether drug use alters dementia risk. Current open programs include a Neuroimaging and CSF Biomarker RFP and Peripheral Biomarkers RFP. Applications are reviewed throughout the year, with a 5:00 p.
m. ET deadline on posted dates.
Get alerted about grants like this
Get emailed when new opportunities from “Alzheimer’s Drug Discovery Foundation” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Funding Opportunities | Alzheimer's Drug Discovery Foundation Young Professionals Committee Annual Reports & Financials Patient & Family Resources Reporting For Funded Projects The ADDF provides funding to academic centers and biotechs from around the world that are advancing therapeutic and biomarker development for Alzheimer's and related dementias. Learn more about our venture philanthropy funding model and areas of focus.
THERAPEUTICS FUNDING PROGRAMS NOW ACCEPTING APPLICATIONS Must be received by 5:00 pm ET on the deadline date. Neuroimaging and CSF Biomarker RFP *For funding related to peripheral or digital biomarkers, see here . DIAGNOSTICS ACCELERATOR PROGRAMS Learn more about the Diagnostics Accelerator here .
For funding related to neuroimaging and CSF biomarkers, see here . ADDF has closed this round of funding and are no longer accepting unsolicited applications. While our current resources are fully committed, we remain dedicated to supporting impactful work and will update this page with new funding opportunities as available.
Peripheral Biomarkers RFP NOW ACCEPTING APPLICATIONS DxA and Target ALS Foundation Biomarker Discovery RFP Must be received by 5:00 pm ET on the deadline date.
OTHER FUNDING OPPORTUNITIES WITH OUR PARTNERS Accelerating Drug Discovery for FTD RFP ADDF-Harrington Scholar Program RFP Treat FTD Fund: Clinical trials for FTD NOW ACCEPTING APPLICATIONS OUR FUNDING MODEL AND FOCUS AREAS NOTE: The ADDF's venture philanthropy model means we make investments, not grants, and use all returns from those investments to support our charitable mission.
Our terms are comparable with those of other venture investors. When we are working with academic institutions, in exchange for our investment we typically ask for a share of any commercial returns that may arise from the funded research. When working with biotechnology companies, we typically purchase Convertible Notes or equity, though we are also open to structuring royalty and milestone agreements with biotechs.
We have dedicated our funding to several key areas: IND-enabling studies and early-stage clinical trials for novel and repurposed drugs Development and validation of plasma, CSF, neuroimaging and digital biomarkers Clinical trials, comparative effectiveness research, and epidemiological studies that test whether the use or choice of drugs alters the risk for dementia or cognitive decline Applications are reviewed throughout the year.
Check back regularly for additional joint funding opportunities with our partners in non-profits, government, and industry. Stay updated on upcoming deadlines and RFP announcements Alzheimer's Drug Discovery Foundation A GuideStar-Rated Charity 57 West 57th Street, Suite 904 Young Professionals Committee Annual Reports & Financials Patient & Family Resources
According to the current listing, eligibility includes: Nonprofits conducting Alzheimer’s drug discovery or biomarker research. Confirm the full requirements in the official notice before applying.
The current listing shows $150,000 prize. Verify award ceilings, matching requirements, and allowable costs in the official notice.
This listing does not include a published deadline, but it is an annual program. Check the official notice for the current cycle's exact dates.
Alzheimer’s Drug Discovery Foundation (Goodes Prize) is funded by Alzheimer’s Drug Discovery Foundation. Verify program details on the funder's official page before applying.
This listing is flagged as international in scope. Check the official notice for country-specific restrictions before applying.
Applications go through the funder's official portal — the Apply Now link on this page goes there directly.
The HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read articleAs of October 1, 2025, NIH no longer posts Notices of Funding Opportunity in the NIH Guide — Grants.gov is now the single official source (NOT-OD-25-143). The weekly Guide table-of-contents email that thousands of investigators relied on to discover funding no longer lists opportunities. Combined with the January 25, 2026 SciENcv certified-PDF requirement, the mechanics of finding and applying for NIH money have changed underneath everyone. Here is how to rebuild your discovery workflow so nothing slips through.
Read articleARPA-H's FASTPASS program targets a public-health blind spot: substandard and contaminated drugs that are only caught after patients are exposed. It funds through-package chemical sensing (TA1 SAMPLE) and the analytics to act on it (TA2 DETECT). The solicitation posts to SAM.gov in mid-August 2026, with a virtual Proposer Workshop on August 24 and registration closing August 20. Here is what FASTPASS funds, why the timing matters, and how to position a cross-disciplinary team.
Read article